Login to Your Account



ESA Restrictions: There will be Blood

By Donna Young


Monday, September 1, 2008
When the FDA on July 30 imposed restrictions on the use of erythropoiesis-stimulating agents (ESAs) in oncology patients, the action appeared to have little impact on Amgen Inc. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription